Use access key #2 to skip to page content.
$26.00 1.13 (4.54%)
7/8/2008 4:00 PM

Amylin Pharmaceuticals, Inc. (AMLN)

CAPS Rating:
**

A biopharmaceutical company committed to improving the lives of people with diabetes, obesity and other diseases through the discovery, development and commercialization of innovative medicines.

View All Commentary (AMLN)

Recs

1

Avatar genedom (97.87) Submitted: 1/30/08 2:28 PM : Outperform Start Price: $29.11 AMLN Score: -3.05

AMLN is pricey at 50, but under 30, it is a bargain.
This is a solid biotech with two drugs in metabolic disease area and a strong pipeline. The revenue growth in the next two year will be slow, which is the reason it is out of market favor now. As time goes by, market will recognize its great science and innovation, I see it over 60 in two years when its pipeline turns to real product.

Report this Post Replies: 0 | Reply

Featured Broker Partners